Location History:
- Haberfield, AU (2021)
- Victoria, AU (2023)
Company Filing History:
Years Active: 2021-2025
Title: Mark Terence Liddament: Innovator in Antibody Research
Introduction
Mark Terence Liddament is a notable inventor based in Haberfield, Australia. He has made significant contributions to the field of antibody research, particularly in the development of anti-PAR-2 antibodies. With a total of 3 patents to his name, Liddament's work has the potential to impact various medical conditions.
Latest Patents
Liddament's latest patents focus on anti-PAR-2 antibodies and their methods of use. These patents disclose antibodies and antigen-binding fragments that specifically bind to human PAR-2. The compositions comprising these antibodies can block the interaction between a PAR-2 activating ligand and the extracellular domain of PAR-2. This innovative approach can be utilized to treat diseases associated with increased expression of PAR-2, including airway diseases, skin diseases, cancer, orofacial granulomatosis, inflammatory conditions, and pain related to various diseases.
Career Highlights
Mark Terence Liddament is currently associated with Cephalon, Inc., where he continues to advance his research in antibody development. His work is characterized by a commitment to addressing significant health challenges through innovative solutions.
Collaborations
Liddament has collaborated with notable colleagues such as Adam Clarke and Bridget Ann Cooksey. These partnerships have contributed to the advancement of his research and the successful development of his patents.
Conclusion
Mark Terence Liddament is a distinguished inventor whose work in antibody research holds promise for treating various medical conditions. His contributions to the field are marked by innovation and collaboration, making him a key figure in the scientific community.